Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 19/20 | 0.60 |
| ▸ | LOX | P28300 | 13/20 | 0.60 |
| ▸ | LOXL3 | P58215 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4770707 | 1.00 | LOXL2 (0.60) | LOXL2LOXLOXL3CYP1A2CYP3A4 | |
| SCHEMBL4550458 | 0.98 | LOXL2 (0.59) | LOXL2LOXLOXL3EPHX2 | |
| SCHEMBL30398543 | 0.98 | LOXL2 (0.59) | LOXL2LOXLOXL3EPHX2 | |
| Hydrochloric Acid SCHEMBL4770701 | 0.97 | LOXL2 (0.57) | LOXL2LOXLOXL3EPHX2 | |
| Hydrochloric Acid SCHEMBL25200556 | 0.87 | LOXL2 (0.58) | LOXL2LOXLOXL3 | |
| SCHEMBL30931697 | 0.85 | LOXL2 (0.56) | LOXL2LOXLOXL3 | |
| SCHEMBL30931725 | 0.85 | LOXL2 (0.60) | LOXL2LOXLOXL3 | |
| Hydrochloric Acid SCHEMBL13570541 | 0.84 | LOXL2 (0.54) | LOXL2LOXLOXL3CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL30931587 | 0.84 | LOXL2 (0.54) | LOXL2LOXLOXL3CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL13570518 | 0.83 | LOXL2 (0.67) | LOXL2LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630404-A1 | UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| US-20250282725-A1 | KCNQ POTENTIATORS | Eii Lilly and Company | 2025-09-11 | — | — | US | disclosed |
| US-12344584-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024121048-A1 | UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| US-20240076269-A1 | KCNQ POTENTIATORS | Eii Lilly and Company (US) | 2024-03-07 | — | — | US | disclosed |
| US-11840516-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2023-12-12 | — | — | US | disclosed |
| EP-3921030-B1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | LILLY CO ELI (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220073464-A1 | KCNQ POTENTIATORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| US-11208383-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3921030-A1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | Eli Lilly and Company (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-113692304-A | 1- ((2- (2,2, 2-trifluoroethoxy) pyridin-4-yl) methyl) urea derivatives as KCNQ enhancers | 礼来公司 | 2021-11-23 | — | — | CN | disclosed |
| WO-2020163268-A1 | 1-((2-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-4-YL)METHYL)UREA DERIVATIVES AS KCNQ POTENTIATORS | ELI LILLY AND COMPANY (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247752-A1 | KCNQ Potentiators | ELI LILLY AND COMPANY (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282725-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20200247752-A1 | KCNQ Potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-12344584-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-11840516-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20240076269-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-11208383-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
| US-20220073464-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | LOXL2 2699/4885LOX 2272/4885LOXL3 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.